At a glance
- Originator Novartis
- Developer Nonindustrial source; Novartis
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2001 Discontinued-Preclinical for Cancer in Switzerland (Unknown route)
- 18 Sep 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 18 May 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)